Drugs / Anti-CD19-CAR γδT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02656147 | Oct 2017 → Apr 2019 | leukemia, lymphoma | Beijing Doing Biomedical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD19-CAR γδT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02656147 ↗ |
| Known as | CD19 CAR γδT-cells | “Following informed consent and registration to the trial, Patients will receive the allogeneic CD19 CAR γδT-cells following lymphodepleting chemotherapy.” NCT02656147 ↗ |
| Modality | Cell therapy | “Advanced Therapy Investigational Medicinal Product named CD19 Chimeric Antigen Receptor (CAR) γδT-cells” NCT02656147 ↗ |
| Target | CD19 | “chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.” NCT02656147 ↗ |